Idiopathic Pulmonary Fibrosis

The Idiopathic Pulmonary Fibrosis pipeline: 7 tracked drugs, 3 approved for this indication.

3 approved / phase 42 Phase 32 preclinical / unstaged

Compare the share prices of listed companies in Idiopathic Pulmonary Fibrosis →

Total attributable cost

$6.5B

$41,652/patient

Drug spend

$3.3B

$21,067/patient

How this is calculated ↗

any · US

The Idiopathic Pulmonary Fibrosis pipeline

← all assets